The Japan Agency for Medical Research and Development has started the "Industry-Academia Collaborative Screening Consortium", an industry-academia collaborative organization that promotes the development of new drugs for cancer, diabetes, etc. in collaboration with domestic pharmaceutical companies and research institutes.From 2016, the new organization will start research toward new drug creation using compounds provided by domestic pharmaceutical companies.
The research will be conducted by forming a team that integrates industry and academia, and the Japan Agency for Medical Research and Development will mediate between the pharmaceutical company and the research institute.In addition, universities and research institutes with the highest technology in Japan will analyze genes and proteins to support research.
With the start of the new organization, researchers are expected to be able to access compounds from multiple pharmaceutical companies at once, increasing the potential for practical application of research.On the other hand, member pharmaceutical companies will have more opportunities to access new drug discovery targets and will be able to increase the potential value of their compounds.
Currently, the formed team is preparing for the investigation, and it will be in operation sequentially from the beginning of the year.
